Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Launched by PFIZER · Sep 21, 2023

Keywords

ClinConnect Summary

This clinical trial is designed for individuals with Multiple Myeloma, a type of blood cancer, who have previously participated in a related study and found benefit from a treatment called elranatamab. The main goal of this study is to continue providing access to elranatamab for those who are still experiencing positive effects from it after their original participation has ended. The trial is currently recruiting participants aged 65 and older, and it welcomes individuals of any gender.

To qualify for this study, participants must have completed a previous study involving elranatamab and must still be benefiting from the treatment at the time their original study ends. However, individuals with certain medical or mental health conditions that could pose risks or who have not previously participated in a qualifying study will not be eligible. Those who join the study can expect to continue receiving elranatamab and will be monitored by healthcare professionals to ensure their safety and well-being throughout the process.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants must agree to follow the reproductive criteria as outlined in the protocol
• • Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deriving clinical benefit from elranatamab (as determined by the investigator).
• Exclusion Criteria:
• • Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
• • Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study.